These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28133990)

  • 1. Economic outcomes with the conversion of insulin delivery methods in hospitals.
    Kelton KA; Perk S; Loveland S; Perez-Nieves M; Fu H; Peng X
    J Med Econ; 2017 May; 20(5):533-540. PubMed ID: 28133990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of converting from 10-mL insulin vials to 3-mL vials and pens in a hospital setting.
    Edmondson G; Criswell J; Krueger L; Eby EL
    Am J Health Syst Pharm; 2014 Sep; 71(17):1485-9. PubMed ID: 25147173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget impact analysis of insulin therapies and associated delivery systems.
    Lee LJ; Smolen LJ; Klein TM; Foster SA; Whiteman D; Jorgenson JA; Hultgren S
    Am J Health Syst Pharm; 2012 Jun; 69(11):958-65. PubMed ID: 22610028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting.
    Eby EL; Smolen LJ; Pitts AC; Krueger LA; Andrews JS
    Consult Pharm; 2014 Dec; 29(12):813-22. PubMed ID: 25521657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
    Asche CV; Luo W; Aagren M
    Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
    Eby EL; Boye KS; Lage MJ
    J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin pens vs. vials and syringes: differences in clinical and economic outcomes.
    Bastian MD; Wolters NE; Bright DR
    Consult Pharm; 2011 Jun; 26(6):426-9. PubMed ID: 21628141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Impact of Converting from Pen and 10-mL Vial to 3-mL Vial for Insulin Delivery in a Hospital Setting.
    Elizabeth E; Smolen L; Pitts A; Krueger LA; Grimm D
    Hosp Pharm; 2014 Dec; 49(11):1033-8. PubMed ID: 25673892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.
    Baser O; Bouchard J; DeLuzio T; Henk H; Aagren M
    Adv Ther; 2010 Feb; 27(2):94-104. PubMed ID: 20352392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization.
    Davis EM; Christensen CM; Nystrom KK; Foral PA; Destache C
    Am J Health Syst Pharm; 2008 Jul; 65(14):1347-57. PubMed ID: 18593681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin pens vs. vials and syringes: the pharmacist's role in individualizing therapy.
    Honebrink AN; Peters CR; Bright DR
    Consult Pharm; 2011 Jul; 26(7):491-3. PubMed ID: 21729850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing insulin vials to pens--comparison of charges, not healthcare benefits.
    Thethi TK
    J Med Econ; 2013 Oct; 16(10):1228-30. PubMed ID: 23926888
    [No Abstract]   [Full Text] [Related]  

  • 13. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.
    Gordon J; McEwan P; Sabale U; Kartman B; Wolffenbuttel BH
    J Med Econ; 2016 Dec; 19(12):1167-1174. PubMed ID: 27356188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
    Clark PE; Valentine V; Bodie JN; Sarwat S
    Curr Med Res Opin; 2010 Jul; 26(7):1745-53. PubMed ID: 20482243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for diabetes: treatment with insulin pen devices.
    Cuddihy RM; Borgman SK
    Am J Ther; 2013; 20(6):694-702. PubMed ID: 21768872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economics analysis of insulin aspart vs. regular human insulin in type 2 diabetes patients, based on observational real life evidence from general practices in Germany.
    Liebl A; Seitz L; Palmer AJ
    Exp Clin Endocrinol Diabetes; 2014 Oct; 122(9):517-22. PubMed ID: 25148263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Insulin Underdelivery from Prefilled and Reusable Insulin Pens in Cases of Premature Needle Withdrawal: A Laboratory Evaluation.
    Joubert M; Haddouche A; Morera J; Rod A; Reznik Y
    Diabetes Technol Ther; 2015 Oct; 17(10):712-6. PubMed ID: 26355757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Converting U-500 regular insulin to insulin detemir and insulin lispro in a patient undergoing dietary changes in preparation for bariatric surgery.
    Nguyen KV; Weidner JA; Shaw KF; Valdez CA
    Am J Health Syst Pharm; 2016 Mar; 73(5):292-7. PubMed ID: 26896501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.